

## THE SHAREHOLDERS' MEETING APPROVES THE 2022 FINANCIAL STATEMENT, THE ALLOCATION OF THE OPERATING RESULT AND THE APPOINTMENT OF A MEMBER OF THE BOARD OF DIRECTORS

*Naples, May 3rd 2023*

The Shareholders' Meeting of **Farmacosmo S.p.A.** ("**Society**", "**Farmacosmo**"), a company active in the Health, Pharma & Beauty sector, listed on the Euronext Growth Milan market of Borsa Italiana, meeting in ordinary session today, has made the following resolutions.

### **APPROVAL OF THE FINANCIAL STATEMENT 2022**

The Shareholders' Meeting approved the financial statements as of December 31st 2022, allocating the loss for the year (amounting to 1,655,197.00 euros) to "loss carried forward." The meeting also viewed the consolidated financial statements of the Farmacosmo Group.

### **NOMINATION OF A MEMBER OF THE BOARD OF DIRECTORS**

On December 29th 2022, following the resignation submitted by administrator Francesco De Concilio, the Company's Board of Directors appointed, by co-optation, independent administrator Doroty de Rubeis, who, in accordance with Article 2386 of the Civil Code, ceased to hold office at today's Shareholders' Meeting.

In view of the above, it was therefore necessary to appoint a new member of the Board of Directors, for the purpose of reconstituting the board plenum, taking into account the number of five members of the Board of Directors resolved by the Shareholders' Meeting when appointing the administrative body on February 4th 2022.

In this regard, the Shareholders' Meeting of Farmacosmo S.p.A. resolved to appoint as a director of the Company lawyer Doroty de Rubeis - who meets the requirements of independence set forth in Article 148, paragraph 3 of the TUF -, with a term of office until the expiration of the term of the current Board of Directors and thus to the date of the Shareholders' Meeting to approve the financial statements for the year ended December 31st 2024.

### **DOCUMENTATION**

The Shareholders' Meeting minutes, the list of names of the participants, and the summary voting statement will be made available to the public within the terms prescribed by current regulations, at the registered office and at Borsa Italiana S.p.A., as well as on the Company's website [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com), in the "Investors/Shareholders' Meetings" section. The Annual Financial Report is available on the website [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com), in the section "Investors/Annual Reports".

\*\*\*

This press release is available on the [www.farmacosmoinvestors.com](http://www.farmacosmoinvestors.com) website, section "Investors/Press Releases" and on the authorized storage mechanism "eMarket Storage" ([www.emarketstorage.com](http://www.emarketstorage.com)).

\*\*\*

### **THE SOCIETY**

Farmacosmo is a company active in the Health, Pharma & Beauty sectors. The company's business model is based on the circular model of the I(ea)n strategy, and is divided into three main business areas: Logistics, Intelligence and Node. Logistics: enables the management and fulfillment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-in time procurement ('zero warehouse' policy). Intelligence: includes strategy definition, competitive positioning and customer journey activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual retail stream turnover. The average cart value of active customers in the retail stream amounted to €92 (€109 related to recurring customers). Node: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its value chain, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to carbon compensation initiatives) and in the valorisation of its employees, the

# FARMACOSMO+

## PRESS RELEASE

company's strategic asset. The portals ProfumeriaWeb, Phàrmasi, Bau Cosmesi and ContactU, an innovative platform of telepsychology launched in March 2023, are part of Farmacosmo Group. During 2022, Farmacosmo launched its rooting strategy through the acquisition of Farmacosmo-branded logistics pharmacies. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

### IDENTIFICATION CODES

Ordinary Share: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

### FOR FURTHER INFORMATIONS:

#### INVESTOR RELATIONS MANAGER

##### Farmacosmo

Via Crispi, 51 - 80121 Napoli

Tel. +39 02 50042143

Paolo Cimmino [ir@farmacosmo.it](mailto:ir@farmacosmo.it)

#### EURONEXT GROWTH ADVISOR

##### Illimity Bank

Via Soperga, 9 - 20124 Milano

Tel. +39 02 82849699

[farmacosmo@illimity.com](mailto:farmacosmo@illimity.com)

#### INVESTOR & MEDIA RELATIONS ADVISOR

##### IR Top Consulting

Via Bigli, 19 - 20121 Milano

Tel. +39 02 45473883

Pietro Autelitano [ir@irtop.com](mailto:ir@irtop.com)

Domenico Gentile [ufficiostampa@irtop.com](mailto:ufficiostampa@irtop.com)